The antibody titer (Figure 1). cination, related for the antibody titer (Figure 1).3.2. Total Anti-S

The antibody titer (Figure 1). cination, related for the antibody titer (Figure 1).3.2. Total Anti-S Antibody Titer and SIR(a) (b)Figure 1. (a) The total anti-S antibodies (PK 11195 Cancer including IgG) to the SARS-CoV-2 spike protein receptor binding domain (RBD) Figure 1. (a) The total antiS antibodies (which includes IgG) for the SARSCoV2 spike protein receptor binding domain (RBD) counts. Information had been measured at 3 and 5 weeks right after initially C6 Ceramide Protocol vaccination and 4 months right after second vaccination. (b) Neutraliz counts. Information have been measured at 3 and five weeks immediately after initial vaccination and four months soon after second vaccination. (b) Neutralizing ing antibodies counts. Data have been measured at 3 and five weeks just after very first vaccination, and four months following second vaccination antibodies counts. Data had been measured at 3 and five weeks following 1st vaccination, and four months right after second vaccination with with an ELISAbased SARSCoV2 Surrogate Virus Neutralization Test Kit. an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.three.3. Difference in Antibody Titer and SIR In line with Gender 3.three. Difference in Antibody Titer and SIR According to Gender Though the distinction in antibody titer was higher in females than in guys (three weeks, Despite the fact that the difference in antibody titer was greater in ladies than in males (three weeks, 96.0 U/mL; five weeks, 2004.6 U/mL; 4 months, 929.three U/mL; versus 3 weeks, 64.5 U/mL; 96.0 U/mL; 5 weeks, 2004.6 U/mL; four months, 929.3 U/mL; versus three weeks, 64.5 U/mL; five five weeks, 1746.7 U/mL; 4 months, 745.3 U/mL), it was not important. The SIR of ladies weeks, 1746.7 U/mL; 4 months, 745.three U/mL), it was not considerable. The SIR of ladies (58.eight ) was significantly higher than that of males (48.7 ) at three weeks, (p 0.05); having said that, (58.8 ) was drastically greater than that of guys (48.7 ) at 3 weeks, (p 0.05); on the other hand, no substantial difference was observed at 5 weeks (95.1 and 93.six for ladies and guys, no considerable distinction was observed at five weeks (95.1 and 93.six for girls and men, respectively) or four months (85.three and 79.four for girls and males, respectively). The SIR respectively) or 4 months (85.three and 79.four for females and guys, respectively). The SIR tended tended to be higher in girls. Even so, each the antibody titer and SIR had been significantlyto be greater in females. Nevertheless, both the antibody titer and SIR had been drastically reduce in both guys and females at four months right after the second vaccination (Figure two and Table 2).Vaccines 2021, 9,4 ofVaccines 2021, 9,decrease in each males and girls at four months right after the second vaccination (Figure two and Table two).four of(a) (b)Figure two. (a) The total antiS antibodies (such as IgG) to the SARSCoV2 spike protein receptorbinding domain (RBD) Figure two. (a) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by gender. Information were measured at three and 5 weeks soon after initially vaccination and four months soon after second vaccination. (b) counts by gender. Data have been measured at three and 5 weeks just after first vaccination and 4 months after second vaccination. Neutralizing antibodies counts by gender. Data had been measured at three and 5 weeks after initial vaccination, and four months right after (b) Neutralizing antibodies counts by gender. Information were measured at three and five weeks right after very first vaccination, and 4 months second vaccination with an ELISAbased SARSCoV2 Surrogate Virus Neutralization Test Kit. just after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit. Table two. Antib.